Magnetic resonance outcome of new enhancing lesions in patients with relapsing‐remitting multiple sclerosis

The aim of the study was to monitor the natural history of new enhancing lesions in multiple sclerosis (MS) by means of serial gadolinium‐enhanced magnetic resonance imaging (MRI). Out of the 63 new enhancing lesions seen on the baseline scan, belonging to 26 relapsing‐remitting MS patients, 26 (40%), nine (14%) and four (6%) lesions showed persisting enhancement at first, second and third follow‐up scan, respectively. At the end of 5 months of follow‐up, 58 (92%) of the new enhancing lesions were detected as T2 hyperintensities, 24 (38%) as T1 hypointensities ('black holes'), and five lesions (8%) disappeared in both T2 and T1 weighted images. Duration of gadolinium enhancement of at least two consecutive scans significantly influenced the development of ‘black holes’. No significant correlation was observed between volume, location, configuration of enhancement at baseline and final outcome of the lesion. In individual cases, different evolution of new enhancing lesions was observed at the same time.

[1]  M W Weiner,et al.  A serial study of new MS lesions and the white matter from which they arise , 1998, Neurology.

[2]  M Filippi,et al.  Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis , 1998, Annals of neurology.

[3]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[4]  G. Comi,et al.  Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium , 1998, Neurology.

[5]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[6]  C. Pozzilli,et al.  MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis , 1997, Multiple sclerosis.

[7]  M. Horsfield,et al.  The influence of clinical relapses and steroid therapy on the development of Gd‐enhancing lesions: a longitudinal MRI study in relapsing—remitting multiple sclerosis patients , 1997, Acta neurologica Scandinavica.

[8]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[9]  F. Barkhof,et al.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.

[10]  C. Pozzilli,et al.  Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[11]  A. Thompson,et al.  A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[12]  F. Barkhof,et al.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.

[13]  H. Tobi,et al.  Correlating MRI and clinical disease activity in multiple sclerosis , 1995, Neurology.

[14]  R. Kikinis,et al.  The evolution of multiple sclerosis lesions on serial MR. , 1995, AJNR. American journal of neuroradiology.

[15]  R. Rudick,et al.  The use of brain magnetic resonance imaging in multiple sclerosis. , 1994, Archives of neurology.

[16]  J. Taubenberger,et al.  Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.

[17]  F. Barkhof,et al.  Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. , 1993, Brain : a journal of neurology.

[18]  T Revesz,et al.  Multiple sclerosis. Pathology of recurrent lesions. , 1993, Brain : a journal of neurology.

[19]  H. McFarland,et al.  Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions , 1993, Annals of neurology.

[20]  Roland Martin,et al.  Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.

[21]  A. Thompson,et al.  Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration , 1992, Neurology.

[22]  P. Scheltens,et al.  Quantitative MRI changes in gadolinium‐DTPA enhancement after high‐dose intravenous methylprednisolone in multiple sclerosis , 1991, Neurology.

[23]  N. Patronas,et al.  Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history , 1991, Annals of neurology.

[24]  C. Pozzilli,et al.  Serial study of gadolinium‐DTPA MRI enhancement in multiple sclerosis , 1990, Neurology.

[25]  H I Goldberg,et al.  Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. , 1988, Radiology.

[26]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[27]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[28]  S. Reingold,et al.  The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.